Pictet Asset Management (Switzerland)’s bluebird bio BLUE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
$15.4M Buy
233,341
+78,103
+50% +$5.71M 0.02% 525
2023
Q1
$9.87M Buy
155,238
+100,685
+185% +$11.5M 0.01% 620
2022
Q4
$7.55M Buy
54,553
+13,699
+34% +$1.93M 0.01% 650
2022
Q3
$5.17M Buy
40,854
+5,210
+15% +$589K 0.01% 731
2022
Q2
$2.95M Buy
35,644
+20,311
+132% +$1.58M ﹤0.01% 876
2022
Q1
$1.49M Buy
15,333
+3,678
+32% +$485K ﹤0.01% 1002
2021
Q4
$2.33M Sell
11,655
-2,978
-20% -$703K ﹤0.01% 980
2021
Q3
$3.62M Buy
+14,633
New +$4.18M ﹤0.01% 910

Other funds holding BLUE

Pictet Asset Management (Switzerland)'s BLUE Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) increased its bluebird bio (BLUE) stake by 50% in Q2 2023, buying an estimated $5.71M and bringing the position to 233,341 shares worth $15.4M. The position accounts for 0.02% of the portfolio, ranked #525.

Pictet Asset Management (Switzerland) first reported a position in BLUE in Q3 2021 and has held it in 8 quarters since. 175 funds tracked by Wall St. Rank hold BLUE as of Q2 2023.

  • Pictet Asset Management (Switzerland) held 233,341 shares of bluebird bio worth $15.4M as of Q2 2023.
  • Pictet Asset Management (Switzerland) bought 78,103 bluebird bio shares in Q2 2023, an estimated $5.71M.
  • bluebird bio made up 0.02% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #525 holding.
  • Pictet Asset Management (Switzerland) first reported a position in bluebird bio in Q3 2021 and has held it in 8 quarters since.
  • 175 funds tracked by Wall St. Rank held bluebird bio as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.